医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nanotronics Health Donates Hundreds of Non-Invasive Ventilators for COVID-19 Relief in India, in Collaboration with Transworld Group

2021年04月29日 PM10:21
このエントリーをはてなブックマークに追加


 

MUMBAI, India & NEW YORK

Nanotronics Health, LLC, a healthcare technology company whose mission is to create and build urgently needed medical devices that are accessible, affordable, easy to use, and intelligently designed, today donated hundreds of nHale™ machines to hospitals in India at Mumbai Municipal Corporation, Navi Mumbai Municipal Corporation, The Govt. of National Capital Territory of Delhi, St. Joseph Hospital Kandla, Lilasha Hospital Kandla and Municipal Corporation of Cochin. The US based company collaborated with Transworld, a global Shipping & Logistics Group, who will utilize top-notch resources to expedite distribution throughout India in response to Covid-19 pandemic.

nHale™ is a bi-level positive air pressure device that was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to support respiratory therapy of spontaneously breathing adults weighing over 30kg suffering from COVID-19 disease. The machine is for use in hospitals, at-home, and in spaces converted for the care of large numbers of COVID-19 patients. nHale™ can be used with or without supplemental oxygen at the prescribing physician’s discretion.

“We want to provide people with the respiratory therapy that they need and free up beds for the most critical patients,” said Ramesh S. Ramakrishnan, Chairman of Transworld Group. “It is critical to quickly and reliably get nHale™ machines to patients either prior to intubated ventilation or moving off of an invasive ventilator.”

Nanotronics Health applied deep in-house expertise to build a machine that is easily manufactured at scale, as well as at reduced cost, to increase accessibility to those in need. The nHale™ device is designed for comfort and ease-of-use with the simplicity of one button.

“We are greatly appreciative of Transworld for partnering with us in this critical humanitarian effort,” said Julie Orlando, President of Nanotronics Health, LLC. “We urge other hospitals to please reach out to us so that we can help get the support that you need.”

National Institute of Health (NIH) COVID-19 treatment guidelines state that noninvasive positive pressure ventilation, such as the nHale™ Bi-Level PAP device, is recommended where high-flow nasal cannula oxygen is not available and endotracheal intubation is not indicated.

About Nanotronics Health, LLC

Nanotronics Health, LLC is a subsidiary of and powered by Nanotronics. The company uses Intelligent Factory Control (IFC) to build and scale medical devices that are affordable, accessible and well-designed. Our first product, nHale™, a non-invasive ventilator, was conceived, built, and obtained Emergency Use Authorization by the FDA within 90 days to treat patients suffering from COVID-19.

About nHale™

The nHale™ is a bi-level positive air pressure device to support respiratory therapy of spontaneously breathing adults weighing over 30kg suffering from COVID-19 disease. It is a non-invasive ventilator designed to be used in non-life-threatening situations, for spontaneously breathing patients, such as a patient in need of breathing assistance but not in need of invasive ventilatory support based on standard medical protocols.

Supplemental oxygen may be used with the nHale™ device to increase the oxygen concentration of the airflow being delivered to the patient only when prescribed and trained by a qualified medical professional. The warnings must be observed when using supplemental oxygen with the nHale™ device.

The machine is for use in traditional healthcare facilities as well as spaces converted for the care of large numbers of COVID-19 patients. The nHale™ is also intended for use in home settings with a doctor’s prescription.

Nanotronics Health LLC, a subsidiary of Nanotronics, applied Nanotronics’ deep in-house expertise, incorporating advanced AI, Intelligent Factory Control (IFC), and sophisticated engineering to build a machine that is easily manufactured at scale and at a reduced cost to increase accessibility for all Americans. The nHale™ device is designed for comfort and ease-of-use with the simplicity of one button.

nHale™ has been authorized by FDA under an Emergency Use Authorization [EUA]; nHale™ is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the device; nHale™ has not been FDA cleared or approved.

nHale™ is a trademark of Nanotronics in the U.S. which can be found at nanotronics.co/nhale.

About Transworld

The Transworld Group is one of the leading shipping and logistics solution providers with a strong presence in the Middle East, Indian Subcontinent and the Gulf Region, operating more than 30 vessels and handling more than 1.2m TEU annually. With strong founding principles of the organization, the Group has grown into a multi-faceted shipping-, marine- and logistics conglomerate in the Region with a commitment for providing the highest level of services to its valued customers. With expertise that covers a complete range of solutions from ship owning (owned and managed fleet of 24 vessels, container/MPP and bulk carriers), feeders, liner, logistics, freight forwarding, multimodal transportation, cold chain, warehousing and end-to-end supply chain management, the Group is a reliable partner for corporations seeking world-class logistics and associated services.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005694/en/

CONTACT

Mary Cunney, Chief Marketing and Communications Officer, Nanotronics Health

mcunney@nanotronics.co

212.401.6209

John Guinipero, Director of Sales, Nanotronics Health

jguinipero@nanotronicshealth.com

+1 203.675.8860

R S Krishnan, Independent Director, Shreyas Shipping and Logistics Ltd, Transworld Group

krish@peakglobalcorp.com

+91 9820045548; +1 443 531 8101

Shipra Saxena, Manager – Corporate Responsibility, Transworld Group

shipra.saxena@transworld.com

+971 564045496

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表